Michele A. Flowers, MD; Jenny Heathcote, MB, BS, MD; Ian R. Wanless, MD; Morris Sherman, MB, BCh, PhD; William J. Reynolds, MD; Ross G. Cameron, MD, PhD; Gary A. Levy, MD; Robert D. Inman, MD
Development of liver disease in chronic hepatitis B virus carriers depends on the interplay between viral products and the host immune system. Although it is generally believed that the virus itself is not cytopathic, most clinical studies document viral replication when the liver disease is progressive. In contrast, chronic carriers of hepatitis B virus who have lost the markers of viral replication usually have static or only slowly progressive liver disease. Reactivation of viral replication in such patients is often associated with an increase in the activity of liver disease. Both spontaneous reactivation and reactivation in association with drug therapy
Flowers MA, Heathcote J, Wanless IR, Sherman M, Reynolds WJ, Cameron RG, et al. Fulminant Hepatitis as a Consequence of Reactivation of Hepatitis B Virus Infection after Discontinuation of Low-Dose Methotrexate Therapy. Ann Intern Med. ;112:381–382. doi: 10.7326/0003-4819-112-5-381
Download citation file:
Published: Ann Intern Med. 1990;112(5):381-382.
Gastroenterology/Hepatology, Infectious Disease, Liver Disease.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use